Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

Shares moves the most in 11-months on a single day basis. Shares of Century Therapeutics Inc IPSC +20.8% Get Free Report ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...